What Arlevert Treats: Main Uses and Benefits

This fixed-dose combination therapy is generally used to provide short-term symptomatic support in adult patients experiencing vertigo and its associated distressing manifestations. The combination is used for the treatment of various kinds of vertigo, focusing on symptom clusters that may become intense or disruptive.

The medication is commonly used across conditions presenting with acute episodes and is relevant for easing symptoms such as spinning sensations (vertigo), disequilibrium, and the associated nausea and vomiting. This supportive management is relevant when short-term symptomatic assistance is needed during acute or disruptive episodes, such as when symptoms create noticeable functional strain. It offers symptomatic relief that may help patients cope more steadily with difficult episodes.

This support for symptoms related to systemic imbalance helps address groups of symptoms that may appear suddenly or fluctuate. It may assist with easing the overall symptom load during periods of heightened symptoms and is relevant for easing general comfort during symptomatic phases where stability becomes momentarily overwhelmed.

Quick Fact: Symptomatic Support for Acute Dizziness The combination is applied when symptoms interfere with daily functioning, and is relevant for managing the core symptom cluster of rotational dizziness and the associated distress from nausea and vomiting during periods of heightened symptoms.

The official regulatory profile for Arlevert (Cinnarizine/Dimenhydrinate) strictly defines patient eligibility based on age, organ function, and pre-existing medical conditions.

Populations for Whom Use is Allowed

The medicine is officially approved and established for use only in adults (18 years and older) for the short-term symptomatic treatment of vertigo [Source 1.1, 1.5]. Older adult patients are permitted to use the medicine with the same dosage regimen as adults [Source 1.5].

Populations for Whom Use is Contraindicated

Use is strictly prohibited (contraindicated) for patients with a known hypersensitivity to the active ingredients or related antihistamines [Source 1.1]. Absolute non-eligibility extends to patients with conditions such as: angle-closure glaucoma, epilepsy (convulsions), suspicion of raised intracranial pressure, alcohol abuse, or urine retention due to prostatic disorders [Source 1.1].

Age and Reproductive Status Limitations

Use is not recommended in children and adolescents under 18 years because the safety and efficacy of the combination have not been established in this age group [Source 1.1, 3.2]. The medicine is also not recommended during pregnancy and should not be used by women who are breastfeeding [Source 1.1, 1.5].

Use is required to be conditional (caution) in patients with mild-to-moderate renal impairment, hypertension, severe coronary heart disease, hyperthyroidism, and Parkinson's disease [Source 1.1, 2.4].

The official interaction profile for Arlevert is structured around specific pharmacodynamic and metabolic risk factors documented in regulatory labeling. Co-administration with certain medicinal products is formally restricted, reflecting classifications found in government sources.

The regulatory documentation advises that the drug's overall effects may be enhanced by co-administered Antihypertensives, Ephedrine, Procarbazine, Tricyclic Antidepressants, and Monoamine Oxidase Inhibitors (MAOIs). This reflects an overall risk of pharmacodynamic potentiation.

A core metabolic risk is identified in the labeling: the dimenhydrinate component formally acts as an inhibitor of CYP2D6 mediated metabolism. This requires caution with co-administered medicines that are substrates of the CYP2D6 enzyme, particularly those with a narrow therapeutic range, as their systemic plasma levels may increase.

Alcohol is documented to potentiate the sedative effects, and patients are formally advised to avoid alcoholic drinks. The medication may also mask ototoxic symptoms associated with aminoglycosidic antibiotics and mask the response of the skin to allergy skin tests. Use is formally restricted in patients with severe hepatic impairment, where drug half-lives are expected to increase, and in those with severe renal impairment (creatinine clearance le 25 mL/min).

Arlevert is a fixed-dose combination containing cinnarizine and dimenhydrinate, which exert effects on both the peripheral and central vestibular systems. Cinnarizine primarily acts as an inhibitor of L-type and T-type voltage-gated calcium channels, particularly in vestibular sensory cells, thereby modulating calcium ion influx and reducing afferent vestibular transmission. Cinnarizine also functions as an antagonist at histamine H1 receptors and, to a lesser extent, muscarinic acetylcholine receptors and dopamine D2 receptors. Dimenhydrinate is a salt of diphenhydramine and 8-chlorotheophylline. The centrally acting diphenhydramine component is a first-generation inverse agonist at central H1 histamine receptors. This antagonism modulates histaminergic neurotransmission in the brainstem vestibular nuclei and the chemoreceptor trigger zone. Furthermore, diphenhydramine exhibits antimuscarinic action by antagonizing acetylcholine receptors. The 8-chlorotheophylline component is hypothesized to contribute to central stimulation through adenosine receptor blockade. The systemic physiological consequence is a bimodal modulation of sensory input processing across the peripheral labyrinth and central vestibular pathways.

Official Administration Guidelines

Arlevert is an oral, fixed-dose combination tablet containing Cinnarizine 20 mg and Dimenhydrinate 40 mg. The administration protocol is defined to ensure standardized use.

Dosing and Administration Method The standard regimen for adults is the oral administration of one tablet, three times daily, establishing a maximum total daily intake of three tablets. A key administration condition is the requirement to take the medicine after meals; this is a procedural step intended to mitigate potential gastrointestinal discomfort. The tablet must be swallowed whole and unchewed, accompanied by liquid.

Duration of Course and Scheduling This medicine is intended for short-term symptomatic use, and the total duration of treatment should generally not exceed four weeks. The three-times-daily frequency dictates a clear, divided-use schedule for the overall treatment course. If a dose is missed, the standard instruction is to omit the forgotten tablet and maintain the established schedule, without taking a double dose.

Use in Specific Populations and Restrictions The standard adult dosing schedule also applies to older adults. However, use is not recommended for children and adolescents under the age of 18 years. There are restrictions for patients with severe organ function limitations, prohibiting use in cases of severe hepatic impairment and severe renal impairment (creatinine clearance le 25 mL/min). The entire protocol structures the standardized application of the medicine.

Research evidence / Overview of studies for Arlevert

Evidence for use in Vestibular Vertigo of Various Origins

The primary research for this fixed-dose combination was evaluated in studies that examined conditions characterized by fluctuating or episodic manifestations of vestibular vertigo. Research has primarily consisted of high-quality short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, often comparing the combination against an inactive placebo, Cinnarizine monotherapy, or Dimenhydrinate monotherapy. Research examined patient-reported outcomes describing perceived discomfort, particularly the overall intensity of the spinning sensation (vertigo) and associated symptoms like nausea and vomiting. Subsequent meta-analyses have observed responses across many of these pivotal short-term trials.

Studies monitored how symptoms evolved in the observed adult populations, particularly in patients reporting symptoms of at least moderate severity. Studies reported measured changes in the patient-reported severity of vertigo and the frequency of accompanying physical discomfort. The research consists primarily of data derived from multiple randomized controlled trials. The research examined outcomes over the initial four-week period, meaning the results apply only to the populations studied.

Evidence in Specific Etiology Subgroups

While the main evidence covers vertigo of various origins, research has explored the combination in studies involving narrower clinical situations as well. Dedicated, targeted trials was studied for patients experiencing vertigo symptoms associated with specific underlying conditions, such as Vertebrobasilar Insufficiency (VBI). In these specific patient subsets, studies monitored outcomes related to systemic or functional imbalance, specifically looking at changes in patient-reported symptom intensity. However, the overall volume of dedicated research for these specific indications is smaller compared to the general vestibular vertigo population, and data for certain groups remain insufficient.

Long-Term Studies and Follow-up Durations

The follow-up durations for the primary, high-quality RCTs were limited, with the most robust efficacy data consistently evaluated after a treatment period of only four weeks. Currently, there is limited information for long-term outcomes beyond this short duration. Long-term effects are not fully established, and while some observational studies have observed responses over extended periods, the high-level evidence from controlled trials primarily provides insight into short-term changes.

Research Gaps and Uncertainty in the Evidence

A key limitation is that the principal outcomes (Mean Vertigo Score) are patient-reported outcomes describing perceived discomfort. Furthermore, data for certain groups remain insufficient. For instance, the main research results apply only to the populations studied—primarily adults—and do not provide extensive data for groups such as children or those with certain severe, complex, or chronic underlying conditions. Research in these areas is still emerging.

Key Studies & References

1. Treatment of Vertebrobasilar Insufficiency–Associated Vertigo with a Fixed Combination of Cinnarizine and Dimenhydrinate
2. Arlevert 20 mg/40 mg tablets: Public Assessment Report (Summary of Product Characteristics and Patient Information Leaflet)

Common questions about Arlevert (FAQ)

Q: Can Arlevert cause long-term side effects?

Official product information indicates that this medicine is for short-term use, generally not exceeding four weeks. Clinical data and regulatory documents primarily focus on this short period, and information regarding long-term effects is limited.

Q: Is it okay to drive or operate machinery while taking Arlevert?

Regulatory documents state that Arlevert may cause drowsiness, especially when you begin treatment. Because of this risk, official guidance includes a warning to avoid driving or operating machinery if you experience drowsiness or are affected by the medicine.

Q: Is Arlevert safe for elderly patients?

The medicine is generally dosed the same for older adults as for younger adults. However, official sources advise caution for patients with conditions aggravated by anticholinergic effects (like glaucoma or prostate enlargement) or conditions like Parkinson’s disease, which are more common in older adults.

Q: Does taking Arlevert affect my blood pressure?

Caution is advised if you have pre-existing high blood pressure (hypertension) or certain heart conditions. Regulatory documents state the medicine may potentiate (increase the effect of) certain drugs taken to lower blood pressure.

Q: Are there any specific foods or drinks I should avoid while taking Arlevert?

Official regulatory documents include a warning about avoiding alcoholic drinks while using Arlevert because alcohol may increase the sedative effects of the medicine.

Q: What should I do if the medicine does not seem to be helping my dizziness?

Since the medicine is intended for short-term symptomatic use, generally not exceeding four weeks, persistent symptoms beyond this period indicate the need for a review of the treatment by a healthcare professional.

Q: Does Arlevert affect sleep patterns?

A very common side effect listed in the official documents is somnolence, which includes feelings of drowsiness or tiredness. Additionally, one of the ingredients (Dimenhydrinate) has been associated with paradoxical excitability (increased agitation or restlessness) in some cases.

Q: What should I look out for as a sign of a serious side effect from Arlevert?

Serious adverse reactions are classified as rare. In the event of signs such as a severe rash (hypersensitivity) or yellowing of the skin or eyes (jaundice), immediate medical attention is indicated according to regulatory guidance.

Q: How quickly should Arlevert start to work after taking it?

Official pharmacokinetic studies show that the active ingredients are rapidly absorbed after taking a dose. They typically reach their maximum concentration in the blood within 2 to 4 hours.

Q: Can Arlevert be used to treat travel sickness?

Official product documentation indicates that this product has not been evaluated in studies for motion sickness (travel sickness).

Q: Can Arlevert cause vision problems?

Yes, impaired vision is listed as a possible side effect of Arlevert, classified as rare (meaning it may affect up to 1 in 1,000 people).

Q: Does Arlevert cause weight gain?

One of the active ingredients, Cinnarizine, has been associated with weight gain as a possible adverse reaction according to official regulatory documents.

Q: Are there studies on Arlevert's use for BPPV (Benign Paroxysmal Positional Vertigo)?

The medicine is officially indicated for the treatment of vertigo symptoms that are vestibular (inner-ear) in origin. This covers a broad range of vestibular disorders, though specific studies for BPPV are not always highlighted in the primary product documentation.

Q: How long do the effects of Arlevert last after one dose?

The elimination half-life for one of the active ingredients, Dimenhydrinate, is estimated to be 5–8 hours. This duration is consistent with the established three-times-daily administration regimen.

Storage and Disposal Requirements

Official regulatory information outlines specific storage and disposal rules to maintain the product's quality and ensure safety.

The medicine is stable until the labeled expiry date (EXP) when stored according to these conditions. Disposing of the product at an approved collection point is the regulatory standard.